Sanofi maintains status quo despite looming Dupixent patent expiration
Despite the approaching patent expiry for its blockbuster drug Dupixent, Sanofi CEO Belén Garijo confirmed there are no plans for a major business or R&D restructuring. The company is focusing on sustaining innovation and pipeline development amid competitive pressures.
Sanofi has announced it will maintain its current business and research and development strategy despite the impending expiration of the patent for Dupixent, a drug that has generated significant revenue since its launch. The company’s CEO, Belén Garijo, confirmed there are no plans for major restructuring in response to the patent cliff, signaling continuity in Sanofi’s approach to innovation and pipeline expansion. Dupixent, approved for conditions such as asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps, has been a cornerstone of Sanofi’s pharmaceutical portfolio. While the exact date of patent expiry is not specified in the available information, it is widely understood to be approaching, which typically triggers intense competition from biosimilar or generic versions.
The decision reflects Sanofi’s long-term strategy to sustain innovation beyond reliance on single blockbuster drugs. The company is investing in its broader pipeline to offset future revenue losses, a move consistent with industry trends where firms diversify to manage patent expirations. Belén Garijo and Sanofi leadership appear focused on maintaining momentum in drug development rather than reacting defensively to market pressures. This stance may be influenced by prior experiences with other high-value drugs nearing expiration, though specific historical comparisons are not detailed in the material.
What remains uncertain is how Sanofi will respond once generic or biosimilar vers
The impending patent expiry of Dupixent could influence drug pricing and patient access, particularly for those with chronic inflammatory conditions who depend on the medication. As biosimilars enter the market, lower-cost alternatives may become available, potentially increasing treatment accessibility—though this depends on regulatory approval timelines and payer reimbursement policies. Sanofi’s decision to maintain its current R&D trajectory suggests confidence in future pipeline success, which could stabilize innovation in rare or complex diseases. However, if new drugs fail to reach market or generate expected revenue, the financial strain may eventually necessitate strategic shifts. A comparable precedent is Pfizer’s experience with Lipitor, where patent loss led to a sharp decline in sales and prompted significant restructuring. While Sanofi appears to be avoiding immediate changes, similar pressures could emerge over time. The broader pharmaceutical industry may respond by acc